Angle PLC Announces Change of Adviser
ANGLE plc (OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the appointment of Cavendish Capital Markets Limited as its new Nominated Adviser and Sole Broker, effective immediately.
The company, which focuses on innovative solutions for research, drug development, and clinical oncology, made this change in its advisory relationships to support its ongoing business operations. The appointment demonstrates ANGLE's commitment to maintaining strong market relationships and corporate governance standards.
ANGLE plc (OTCQX:ANPCY), azienda leader nel campo delle biopsie liquide specializzata nelle soluzioni per cellule tumorali circolanti (CTC), ha nominato Cavendish Capital Markets Limited come nuovo Nominated Adviser e Sole Broker, con effetto immediato.
L'azienda, focalizzata su soluzioni innovative per la ricerca, lo sviluppo di farmaci e l'oncologia clinica, ha riorganizzato i propri rapporti di consulenza per sostenere le attività operative in corso. La nomina sottolinea l'impegno di ANGLE a mantenere solide relazioni di mercato e elevati standard di governance aziendale.
ANGLE plc (OTCQX:ANPCY), compañía líder en biopsias líquidas especializada en soluciones para células tumorales circulantes (CTC), ha nombrado a Cavendish Capital Markets Limited como su nuevo Nominated Adviser y Sole Broker, con efecto inmediato.
La empresa, que se centra en soluciones innovadoras para la investigación, el desarrollo de fármacos y la oncología clínica, ha ajustado sus relaciones de asesoramiento para respaldar sus operaciones comerciales en curso. El nombramiento refleja el compromiso de ANGLE de mantener sólidas relaciones en el mercado y altos estándares de gobierno corporativo.
ANGLE plc (OTCQX:ANPCY), 순환종양세포(CTC) 솔루션을 전문으로 하는 선도적인 액체생검 기업이 Cavendish Capital Markets Limited를 새로운 Nominated Adviser 및 단독 중개인(Sole Broker)으로 즉시 임명했습니다.
연구, 신약 개발 및 임상 종양학을 위한 혁신적 솔루션에 주력하는 이 회사는 지속적인 사업 운영을 지원하기 위해 자문 관계를 변경했습니다. 이번 임명은 ANGLE이 시장 관계 강화와 기업 지배구조 기준 유지를 중요하게 여긴다는 점을 보여줍니다.
ANGLE plc (OTCQX:ANPCY), société de premier plan dans le domaine de la biopsie liquide spécialisée dans les solutions pour cellules tumorales circulantes (CTC), a nommé Cavendish Capital Markets Limited comme nouveau Nominated Adviser et Sole Broker, avec effet immédiat.
L'entreprise, qui se concentre sur des solutions innovantes pour la recherche, le développement de médicaments et l'oncologie clinique, a modifié ses relations de conseil afin de soutenir ses activités commerciales en cours. Cette nomination illustre l'engagement d'ANGLE à maintenir de solides relations de marché et des normes élevées de gouvernance d'entreprise.
ANGLE plc (OTCQX:ANPCY), ein führendes Unternehmen im Bereich der Liquid Biopsy mit Spezialisierung auf Lösungen für zirkulierende Tumorzellen (CTC), hat Cavendish Capital Markets Limited mit sofortiger Wirkung zum neuen Nominated Adviser und Sole Broker ernannt.
Das Unternehmen, das sich auf innovative Lösungen für Forschung, Arzneimittelentwicklung und klinische Onkologie konzentriert, hat seine Beratungsbeziehungen neu geordnet, um seine laufenden Geschäftsaktivitäten zu unterstützen. Die Ernennung unterstreicht ANGLEs Verpflichtung zu stabilen Marktbeziehungen und hohen Standards der Unternehmensführung.
- None.
- None.
APPOINTMENT OF NOMINATED ADVISER AND SOLE BROKER
GUILDFORD, SURREY / ACCESS Newswire / September 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has appointed Cavendish Capital Markets Limited as the Company's Nominated Adviser and Sole Broker with immediate effect.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Cavendish (NOMAD and Broker) | +44 (0) 20 7220 0500 |
FTI Consulting |
|
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.
Over 115 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on ACCESS Newswire
FAQ
Who is ANGLE plc's new Nominated Adviser and Broker as of September 2025?
What does ANGLE plc (OTCQX:ANPCY) specialize in?
When did ANGLE plc announce their new advisory appointment?
Who are the key contacts for ANGLE plc's corporate communications?
